Open AccessA phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
Author(s) -
Miso Kim,
Jeong-Ok Lee,
Jiwon Koh,
Ji Yun Lee,
Yoon Kyung Jeon,
Bhumsuk Keam,
Dong Wan Kim,
Jong Seok Lee,
Dae Seog Heo
Publication year - 2021
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.278301
Subject(s) - brentuximab vedotin , cd30 , refractory (planetary science) , medicine , oncology , epstein–barr virus , virology , virus , lymphoma , biology , astrobiology
Not available.